Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

Financial Info
: Financials

Financials

v3.19.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Current assets:    
Cash $ 25,034 $ 25,496
Prepaid expenses and other 1,022 947
Total current assets 26,056 26,443
Property and equipment, net 43 91
Restricted cash 100 89
Intangible Asset 120 120
Security deposits   11
Total assets 26,319 26,754
Current liabilities:    
Accounts payable 1,404 1,296
Accrued expenses 1,251 830
Total current liabilities 2,655 2,126
Deferred rent payable   12
Total liabilities 2,655 2,138
Commitments (See Note 9)  
Stockholders' equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series A Convertible Preferred stock, $0.001 par value; 11,984 shares designated; 9,856 and 0 shares issued and outstanding as of December 31, 2018 and 2017, respectively  
Common stock, $0.001 par value; 15,000,000 shares authorized; 3,251,970 and 785,874 shares issued and outstanding as of December 31, 2018 and 2017, respectively, and 1,758 shares to be issued as of December 31, 2018 3 1
Additional paid in capital 212,154 186,990
Accumulated deficit (188,452) (162,363)
Accumulated other comprehensive loss (41) (12)
Total stockholders' equity 23,664 24,616
Total liabilities and stockholders' equity $ 26,319 $ 26,754
v3.19.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
COSTS AND EXPENSES:    
Research and development $ 17,558 $ 13,342
General and administrative 8,764 7,949
Total costs and expenses 26,322 21,291
Operating Loss (26,322) (21,291)
Interest income, net 233 168
Net loss (26,089) (21,123)
Preferred stock deemed dividend 3,266  
Net loss available to common stockholders $ (29,355) $ (21,123)
Net loss per common share, basic and diluted (in dollars per share) $ (26.81) $ (31.69)
Weighted average common shares outstanding, basic and diluted (in shares) 1,094,867 666,509
v3.19.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (26,089) $ (21,123)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 54 70
Stock-based compensation 1,627 1,790
Changes in operating assets and liabilities:    
Prepaid expenses (79) 72
Accounts payable 106 424
Accrued expenses and deferred rent 410 (361)
Net cash used in operating activities (23,971) (19,128)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of furniture and fixtures (6) (5)
Maturities of marketable securities   7,174
Net cash provided by investing activities (6) 7,169
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercise of warrants   14
Proceeds, net of $1,159 expenses, from sale of preferred stock 10,825  
Proceeds, net of $610 and $1,183 expenses, from sale of common stock 12,714 18,505
Net cash provided by financing activities 23,539 18,519
Effect of currency rate change on cash (13) (5)
Net (decrease) increase in cash, cash equivalents and restricted cash (451) 6,555
Cash, cash equivalents and restricted cash beginning of the year 25,585 19,030
Cash, cash equivalents and restricted cash end of year 25,134 25,585
Supplemental disclosures of cash flow information:    
Taxes paid 82 65
Non cash financing activities:    
Issuance of common stock under employee benefit plan   $ 74
Beneficial conversion feature in connection with sale of Series A Convertible preferred stock and deemed dividend $ 3,266